The big dark themes of the opening film “White Noise” continue on the second day of the festival – with fictitious biographies once morest a real background. Bardo is Alejandro G. Iñárritu’s first Mexican film since his big screen debut, Amores Perros. After five international films, the Oscar-winner has taken on a personal story regarding a celebrated middle-aged filmmaker visiting his homeland.
Even if the protagonist Silverio is a journalist and documentarist: the balance of life at a peak, the struggle with life as an emigrant including the political identity crisis, critical attitude towards the old homeland and the male role within the family, all of this is told very honestly. Whether the Netflix streaming group will win the Golden Lion once more following Alfonso Cuarón’s “Roma” in 2018 with “Bardo” remains to be seen. The film is an opulent throwback; with a big budget and lots of extras. Partly the narrative seems spread out, then Iñárritu summarizes the scenes in the playful language of magical realism, in visually impressive wide-angle shots with exaggerated CGI effects.
Monthly Archives
September 2022
Details of a Saudi businessman being defrauded of 2.5 million pounds in Cairo!
written by Alexandra Hartman Editor-in-Chief
Al-Marsad newspaper: A Saudi businessman filed an urgent complaint with the Egyptian security authorities following being subjected to fraud by an Arab resident in Cairo, with an amount touching 2.5 million Egyptian pounds, according to “Previously”.
The businessman, Dr. Fahd Al-Joufi, had met the Arab resident and signed with him all the legal documents to start investing the amount in accordance with the Egyptian investment regulations, but he was surprised by the Arab resident’s disappearance, which prompted him to file a complaint immediately.
Al-Jawfi assigned his lawyer, Legal Counsel Nasser Hegazy, with an invitation to the First Settlement Police, and the case was referred to the Public Prosecution, and the report No. 12407, Administrative of the First Settlement Police Department, to complete the necessary investigations regarding the fraud and fraud.
He added: “The report is now a party to the head of the administrative records to present it to the department’s investigations to make the necessary investigations.”
Moscow: India, China, Russia begin joint military exercise – Vostok in Russia despite US opposition. This month will last till seven.
7/8 Gurkha Rifles are participating in the military exercise on behalf of the Indian Army. 50,000 soldiers will participate in military exercises near the Sea of Japan. 140 aircraft and 60 warships are participating in the exercise. White House Press Secretary Karin Jean-Pierre responded that India’s decision to participate in the military exercise was disappointing. US says cooperation with Russia at war with Ukraine sends wrong message clarified.
Hemophilia is a hereditary disease linked to the deficiency of a coagulation factor (factor VIII for hemophilia A, factor IX for hemophilia B). In the hemophiliac patient, the coagulation process is therefore compromised and if the patient does not bleed more, he bleeds longer. In some patients, recurrent bleeding into the joints can also lead to progressive joint damage and arthritis. If there is no definitive treatment for the disease, prophylactic treatments or in the event of a haemorrhagic accident, by intravenous injections of the failing coagulation factor, make it possible to prevent or stop the haemorrhage. Finally, the gene responsible for the production of coagulation factor IX being located on the X chromosome, severe forms of hemophilia B are much more frequent in men.
This novel adeno-associated virus (AAV) gene therapy, called FLT180a
opens up hope for patients to be able to do without regular and necessary injections of recombinant coagulation factor, which helps prevent excessive bleeding.
The B-AMAZE clinical trial multicenter phase I/II, carried out on 10 patients diagnosed with hemophilia B, confirms that a single injection of FLT180a leads to sustained production of coagulation factor by the liver in 9 out of 10 patients. Professor Pratima Chowdary of the UCL Cancer Institute comments on these good results: “Eliminating the need for haemophilia patients to regularly inject the missing protein is an important step in improving their quality of life”.
AAV gene therapy works by using the outer envelope of the virus, to deliver a working copy of a gene directly to the patient’s tissues to compensate for one that is not working properly. The synthesized proteins are released into the blood and a single infusion can induce lasting effects. However, patients must take immunosuppressive drugs for several weeks to several months to prevent their immune system from rejecting the therapy. The trial shows that while the treatment was generally well tolerated, all patients experienced some form of adverse event, with an abnormal blood clot in the one who received the highest dose of FLT180a and who had the levels the highest in clotting protein.
“Gene therapy remains a young but promising field for people with serious genetic diseases. These initial data from the B-AMAZE trial add to the growing body of evidence that gene therapy has the potential to free patients from lifelong therapies.”
The ongoing follow-up study should assess the durability of the therapeutic efficacy and monitor the occurrence of any longer-term side effects.